Leflunomide Sandoz

Leflunomide, the active ingredient in Leflunomide Sandoz, is an immunomodulatory agent presented as an oral tablet for systemic use. It is used to treat rheumatoid arthritis in adult patients by modifying disease progression and reducing inflammatory symptoms. It belongs to the disease-modifying antirheumatic drug (DMARD) class and is approved in the European Union for long-term management of rheumatoid arthritis.

GNH USA supplies Leflunomide Sandoz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable supply chains to meet global demand.

Leflunomide is a disease-modifying antirheumatic drug (DMARD) used primarily in rheumatology.

Rheumatoid arthritis (moderate to severe): reduces joint inflammation and slows structural damage. Early rheumatoid arthritis: helps achieve disease control when combined with other DMARDs. Active rheumatoid arthritis: improves functional ability and reduces pain.

Leflunomide may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Diarrhea: loose stools or increased frequency. - Nausea: feeling of sickness or urge to vomit. - Headache: mild to moderate cranial pain. - Hypertension: elevated blood pressure readings. - Alopecia: thinning or loss of hair. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver enzyme elevations or liver injury. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Bone marrow suppression: decreased blood cell counts. - Severe hypertension: markedly high blood pressure that may lead to complications.

Before initiating therapy, clinicians should evaluate several safety parameters and monitor patients regularly.

Monitor liver function: obtain baseline and periodic liver enzyme tests. Check blood pressure: measure regularly and manage elevations. Assess for infections: avoid starting therapy in patients with active infections. Avoid use in severe hepatic impairment: contraindicated in significant liver disease. Pregnancy and breastfeeding: discuss potential risks with the prescriber. Store at ambient temperature: keep in the original container, protect from moisture and heat.

Leflunomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Methotrexate: increased risk of hepatotoxicity. - Warfarin: potentiated anticoagulant effect, raising bleeding risk. - Live vaccines: heightened risk of severe infection.

Moderate Interactions (Monitor Closely): - Statins: possible myopathy when combined. - Azathioprine: additive bone marrow suppression.